Nautilus Biotechnology reports Q3 2026 financial results

Nautilus Biotechnology has released its third quarter 2026 financial results, reporting revenue of $0.2 million. This revenue was primarily driven by grant activities related to The Michael J. Fox Foundation and services from its Iterative Mapping Early Access Program.

The company reported a net loss of $15.6 million, compared to $13.6 million in the same period last year, while operating expenses rose 10% to $16.9 million. As of September 30, 2026, Nautilus held $114.3 million in cash, cash equivalents, and investments.

On the research front, Nautilus published a paper in Nature Methods regarding its Iterative Mapping technology and presented oncology proteoform assay data at World HUPO 2026. Additionally, the company announced its participation in the ARPA-H-funded SEEDS research consortium. Nautilus expects to receive up to $6 million through this four-year program to utilize its Voyager Platform for measuring proteoforms linked to Alzheimer’s disease and Ewing sarcoma.